General Information
Drug ID
DR00416
Drug Name
Cytarabine
Synonyms
(beta-D-Arabinofuranosyl)cytosine; 1-.beta.-D-arabinofuranosyl-cytosine; 1-Arabinofuranosylcytosine; 1-beta-D-Arabinofaranosylcytosine; 1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone; 1-beta-D-Arabinofuranosylcytosine; 1-beta-D-Arabinofuranosylcytosine, Cytosine Arabinoside; 1-beta-D-Arabinosylcytosine; 1beta-Arabinofuranasylcytosine; 1beta-D-Arabinofuranosylcytosine; 1beta-D-Arabinosylcytosine; 2(1H)-Pyrimidinone, 4-amino-1-D-arabinofuranosyl-[CAS]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin [Czech]; 4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine; 4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinon [Czech]; 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone; 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one; AR3; Alexan; Ara-C; Ara-C, Cytosine Arabinoside, Cytosar-U, Cytarabine; Ara-Cytidine; AraC; Arabinocytidine; Arabinofuranosylcytosine; Arabinosyl Cytosine; Arabinosylcytosine; Arabitin; Aracytidine; Aracytin; Aracytine; Arafcyt; BTB15125; Beta-Ara C; Beta-Arabinosylcytosine; Beta-D-Arabinosylcytosine; Beta-cytosine arabinoside; CHX 3311; CYTARABINE (SEE ALSO CYTARABINE HYDROCHLORIDE 69-74-9); Citarabina; Citarabina [INN-Spanish]; Cytarabin; Cytarabina; Cytarabine (JP15/USP/INN); Cytarabine [USAN:INN:BAN:JAN]; Cytarabine liposome injection; Cytarabinoside; Cytarabinum; Cytarabinum [INN-Latin]; Cytarbel; Cytonal; Cytosar; Cytosar-U; Cytosar-U (TN); Cytosine 1-beta-D-arabinofuranoside; Cytosine arabinofuranoside; Cytosine arabinose; Cytosine arabinoside; Cytosine arabinoside (VAN); Cytosine beta-D-arabinofuranoside; Cytosine beta-D-arabinofuranoside hydrochloride; Cytosine beta-D-arabinoside; Cytosine, beta-D-arabinoside; Cytosine-1-beta-D-arabinofuranoside; Cytosine-beta-D-arabinofuranoside; Cytosine-beta-arabinoside; Cytosinearabinoside; DepoCyte; Depocyt; Depocyt (TN); Depocyt (liposomal); Erpalfa; Intrathecal (injected into the spinal fluid) DepoCyt; Intrathecal cytarabine (also known as ara-C); Iretin; Spongocytidine; Tarabine; U 19920A; U-19,920; U-19920; Udicil
Drug Type
Small molecular drug
Indication Acute lymphoblastic leukemia [ICD11: 2B33.0] Approved [1]
Chronic myelogenous leukemia [ICD11: 2A20.0] Approved [1]
Acute myeloid leukemia [ICD11: 2A60] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=6253"></iframe>
3D MOL 2D MOL
Formula
C9H13N3O5
Canonical SMILES
C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
InChI
InChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
InChIKey
UHDGCWIWMRVCDJ-CCXZUQQUSA-N
CAS Number
CAS 147-94-4
Pharmaceutical Properties Molecular Weight 243.219 Topological Polar Surface Area 129
Heavy Atom Count 17 Rotatable Bond Count 2
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 5
XLogP
-2.1
PubChem CID
6253
PubChem SID
103210760 , 103986361 , 104253284 , 104311532 , 11528303 , 11533128 , 117529237 , 118048876 , 12146044 , 124648720 , 124757405 , 124799562 , 14774115 , 15196510 , 24858315 , 24892435 , 26527898 , 26719755 , 29215144 , 29225249 , 3260118 , 46386862 , 46505879 , 47193873 , 47573376 , 48415837 , 49831046 , 50105698 , 53787662 , 56310997 , 56311029 , 56312269 , 56312943 , 56313129 , 56313612 , 5877 , 598052 , 76890970 , 7847236 , 7885952 , 7979015 , 8153933 , 829245 , 83110442 , 87558791 , 90341066 , 92308449 , 92309014 , 93166529 , 93167157
ChEBI ID
ChEBI:28680
TTD Drug ID
D07XSN
DT(s) Transporting This Drug CNT1 Transporter Info Concentrative nucleoside transporter 1 Substrate [2]
ENT1 Transporter Info Equilibrative nucleoside transporter 1 Substrate [2]
ENT2 Transporter Info Equilibrative nucleoside transporter 2 Substrate [2]
OCT1 Transporter Info Organic cation transporter 1 Substrate [3]
OCTN1 Transporter Info Organic cation/carnitine transporter 1 Substrate [4]
P-GP Transporter Info P-glycoprotein 1 Substrate [5]
References
1 Cytarabine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 FLT3 is implicated in cytarabine transport by human equilibrative nucleoside transporter 1 in pediatric acute leukemia. Oncotarget. 2016 Aug 2;7(31):49786-49799.
3 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4 OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues. Cancer Res. 2017 Apr 15;77(8):2102-2111.
5 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.